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Leishmania donovani is the causative agent of visceral leishmaniasis, also known as Kala-Azar, a generalised 
infection that causes persistent fever, weight loss, anaemia, and hepato-spleno-megaly in alicted humans and 
has a fatal outcome in untreated and treatment failure cases. he annual global incidence is estimated as between 
300,000 and 400,000 cases with up to 30,000 fatalities1.
he L. donovani life cycle is bipartite, with a lagellated, elongated promastigote stage that proliferates in the 
digestive tract of the transmitting sand lies, and an ovoid, alagellated intracellular stage, the amastigote, which 
proliferates inside mammalian phagocytic cells. he conversion between the life cycle stages is crucial for parasite 
survival in sand lies and mammalian hosts and triggered by changes in the environment, i.e. temperature and 
pH. In keeping with this, L. donovani promastigotes can be triggered into amastigote conversion by elevated cul-
ture temperatures combined with acidic growth medium2.
An elevated cultivation temperature also causes an increased synthesis of several parasite heat shock pro-
teins3–8 suggesting their involvement in intracellular survival and life cycle control. Heat shock proteins also 
play other decisive roles in the intracellular amastigote stage, being a prominent part of the protein payload 
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of immune modulatory secreted vesicles known as exosomes. Nearly all major chaperones, including HSP90, 
HSP70, CPN60.2 and CPN60.3, STIP1 and HSP100 are released into the host cell cytoplasm, with the latter play-
ing a crucial role in the sorting of exosome content. Lack of chaperones in the exosomes abrogates their immune 
modulatory potential9,10.
Chaperone proteins of the HSP90 family play well known roles in the maturation and activation of a multitude 
of regulatory proteins, such as transcription factors, protein kinases, hormone receptors and cytoskeletal pro-
teins11,12 and can even silence mutations in regulatory proteins13.
Consequently, HSP90 is an essential protein in all eukaryotic organisms precluding the viability of HSP90 
null mutants in any known system. Moreover, HSP90 is a highly abundant protein species, accounting for up to 
3% of a cell’s total protein3,14. herefore, reverse genetics approaches, i.e. creating null mutants, to unravel the 
role and function of HSP90 are likely to fail. he discovery of the HSP90-speciic inhibitor geldanamycin (GA)15 
allowed the pharmacological inactivation of this protein family and the study of the phenotypical consequences 
in tumor cell lines16–19, but also in parasitic microorganisms such as Leishmania donovani, Trypanosoma cruzi, 
and Plasmodium falciparum20–22. Geldanamycin has a speciic ainity for the HSP90 ATP-binding pocket, an 
ainity it shares with another speciic inhibitor, radicicol (RAD)23,24. Both inhibitor classes cause a cell cycle arrest 
in logarithmically growing culture cells and indirectly inhibit the maturation and function of HSP90-dependent 
client proteins, initially ofering great promise as anti-cancer drugs25. In Leishmania donovani, pharmacological 
inhibition of HSP90 can induce morphological and biochemical promastigote-to-amastigote diferentiation20,26,27, 
mimicking the known environmental triggers, i.e. heat shock and low pH, and indicating a pivotal role for HSP90 
in environmental sensing and life cycle control.
HSP90 is usually found as a dimer in large complexes known as foldosomes. In their function they depend on 
ATP hydrolysis and on a cohort of so-called co-chaperones that assist in the recruitment of client proteins and in 
the regulation of the HSP90 reaction cycle28,29. he HSP90 foldosome can vary in composition depending on the 
client proteins, but usually includes subunits such as HSP70/40, P23, AHA1 and STIP1 (HOP)29. HSP90, HSP70 
and STIP1 are also known as substrates of protein kinases30–32, afecting function and subcellular localisation of 
these chaperones.
Leishmania spp also possess an almost complete set of co-chaperones, with the notable absence of CDC-
37, but including the essential co-chaperones STIP1, SGT27,29,33–35 and others with less impact on the viability, 
such as HIP, P23, and AHA136–38. he HSP90 and HSP70 chaperones, but also co-chaperones such as STIP1 and 
cyclophilin 40, have been shown to be phosphorylated during amastigote stage conversion34,39. Mutagenesis of 
two phosphorylation sites (P-sites) in L. donovani STIP1 caused either general lethality or no phenotype at all34. 
Mutation of the single P-site in cyclophilin 40 had no phenotypic consequences40.
HSP90 is involved in a variety of diverse cellular processes and its complex functions are highly regulated by 
post-translational modiications, such as phosphorylation, acetylation, SUMOylation, methylation, ubiquitina-
tion and s-nitrosylation31,41. Phosphorylation of HSP90 does not only regulate its activity directly, but also its 
interaction with other chaperones, co-chaperones, nucleotides and client proteins32,42–45. he kinases responsible 
for phosphorylation of HSP90 include double-stranded DNA protein kinase, B-raf, Akt, c-Src, protein kinase A, 
SweWee1, GSK-3beta, casein kinase 1 and casein kinase 231,32.
Essential protein kinases are discussed as attractive drug targets against cancer but also against infectious 
diseases, such as leishmaniasis. In Leishmania, a variety of kinases have already been identiied as potential drug 
targets, such as mitogen-activated protein kinases (MAPKs), cdc-related kinase 3 (CRK3) and GSK346–50. he 
members of the Leishmania casein kinase 1 (CK1) family have also emerged as potential drug targets51. he CK1 
family consists of multifunctional Ser/hr protein kinases, characterised by a highly conserved kinase domain 
and a speciic C-terminal domain responsible for kinase regulation and localisation52. CK1 isoform 2 (CK1.2) 
of L. donovani was identiied as exokinase released via immune-modulatory exosomes into the host cell cytosol, 
where it may phosphorylate and modulate host cell proteins9,10,53–55. his kinase was shown to be essential for 
intracellular parasite survival.
hus far, Leishmania kinases and phosphatases involved in HSP90 modiication are poorly understood. 
Nevertheless, a recent study demonstrated that the L. donovani MAPK1, whose L. mexicana orthologue is 
involved in parasite viability and drug resistance56, interacts with HSP90 and HSP70, afects the expression of 
HSP90 and HSP70 and phosphorylates both chaperones in vitro57. Given the co-localisation of HSP90 and other 
major chaperones with CK1.2 in the exosome export pathway10, this kinase may also act as upstream kinase for 
HSP90 regulation.
Thus far, three phosphorylation sites have been identified in the L. donovani HSP90, Thr223, Ser526 and 
hr216
34,58, all showing increased modiication during promastigote-to-amastigote diferentiation. However, an 
analysis of the impact of phosphorylation on HSP90, a key regulator of the Leishmania life cycle20, was hindered 
so far by the high copy numbers of HSP90-coding genes in Leishmania59 and the essential nature of HSP90. 
However, the introduction of an inhibitor-resistant sequence variant of L. donovani HSP90, allowing a conditional 
mutagenesis of this protein27, has paved the way for an analysis of HSP90 phosphorylation sites and their impact 
on itness, morphology and infectivity. Also, the ability of CK1.2 to phosphorylate HSP90 in vitro was tested on a 
panel of phosphorylation site mutants, identifying at least one CK1.2-speciic site.

Ƥ ? ?ǦǤ he P-sites at hr223 and Ser526 were identiied in L. 
donovani HSP90 by phosphoproteome analysis34.
To identify further phosphorylation sites within the Leishmania HSP90, phosphoproteomics analyses were 
performed on cultured promastigotes, in vitro differentiated axenic amastigotes and mouse-lesion-derived 
amastigotes of L. mexicana. his led to the identiication of seven previously unknown phosphorylation sites at 
hr211, hr216, Ser289, Ser526, Ser594 and Ser595. Fragmentation spectra can be found in the supplementary material 
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(Fig. S1). All sites are conserved in L. donovani (Fig. 1A). he hr223 P-site of L. donovani is not conserved in L. 
mexicana.
We also identiied putative P-sites by literature search and sequence alignments. Two P-sites at hr22 and hr101 
are located in the ATP-binding pocket of the S. cerevisiae HSP90, and hr to Ile exchanges afect the ATPase activ-
ity of ScHSP9043,60. In L. donovani HSP90, these residues are conserved at positions hr21 and hr100 and were 
mutated identically, namely hr21 to Ile21 and hr100 to Ile100.
he putative P-sites at hr693 and Ser694 were inferred from the known P-sites hr725 and Ser726 in the human 
cytosolic αHSP90 32. A list of the serine and threonine residues targeted for replacement with non-modiiable 
alanine and/or phosphomimetic aspartate is shown in Table 1 and schematically in Fig. 1.
We have previously established a system for a conditional phenotype analysis of HSP90 mutants in vitro. 
Briely, a Leu33Ile mutant of HSP90, dubbed HSP90rr, was created which is resistant to the HSP90-speciic inhib-
itor RAD. Ectopic expression of HSP90rr from episomal transgenes has no efect under normal culture condi-
tions, but under RAD challenge, HSP90rr facilitates normal growth, morphology and infectivity. Any mutation 
introduced into HSP90rr only shows a phenotype under RAD challenge when the endogenously coded HSP90 
is inactivated27.
Figure 1. Schematic representation of the targeted phosphorylation sites and domain organisation of HSP90. 
(A) HSP90 sequence alignment for L. donovani (LdBPK_330360.1) and L. mexicana (LmxM.32.0314). 
Phosphorylation sites (see Table 1) are highlighted. (B) Putative domain architecture of HSP90 and distribution 
of phosphorylation sites over N-terminal (ND), charged linker (CLD), middle (MD) and C-terminal domain 
(CD). Standard one-letter amino acid codes apply.
Position Reference
Constitutive de-
phosphorylation
Phosphomimetic 
exchange Surrounding Sequence
hr21 (Mollapour et al., 2011) hr21 – Ile21 hr21 – Asp21 Ser-Leu-Ile-Ile-Asp-hr-Phe-Tyr-Ser-Asn-Lys
hr100 (Hawle et al., 2006) hr100 – Ile100 hr100 – Asp100 Ile-Ala-Arg-Ser-Gly-hr-Lys-Ala-Phe-Met-Glu
hr211 this paper hr211 – Ala211 hr211 – Asp211 Met-Val-Glu-Lys-hr-hr-Glu-Lys-Glu-Val-hr
hr216 this paper hr216 – Ala216 hr216 – Asp216 hr-Glu-Lys-Glu-Val-hr-Asp-Glu-Asp-Glu-Glu
hr223 (Morales et al., 2010) hr223 – Ala223 hr223 – Asp223 Glu-Asp-Glu-Glu-Asp-hr-Lys-Kys-Ala-Ala-Glu
Ser289 this paper Ser289 – Ala289 Not done Phe-Tyr-Lys-Ala-Ile-Ser-Asn-Asp-Trp-Glu-Asp
Ser526 (Morales et al., 2010) Ser526 – Ala526 Not done Val-His-Phe-Glu-Glu-Ser-Glu-Glu-Glu-Lys-Gln
Ser594 this paper Ser594 – Ala594 Ser594 – Asp594 Gln-Ala-Lys-Arg-Asp-Ser-Ser-Met-Ala-Gln-Tyr-Met
Ser595 this paper Ser595 – Ala595 Ser595 – Asp595 Gln-Ala-Leu-Arg-Asp-Ser-Ser-Met-Ala-Gln-Tyr-Met
hr693 (Muller et al., 2013) hr693 – Ala693 hr693 – Asp693 Glu-Val-hr-Ala-Gly-hr-Ser-Ser-Met-Glu-Gln-Val-Asp
Ser694 (Muller et al., 2013) Ser694 – Ala694 Ser694 – Asp694 Glu-Val-hr-Ala-Gly-hr-Ser-Ser-Met-Glu-Gln-Val-Asp
Table 1. List of the Ser and hr residues in HSP90 that were subjected to mutagenesis. hree-letter amino acid 
codes apply.
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Using a non-commercial procedure for targeted mutagenesis27 and speciic oligonucleotide primer pairs for 
each target sequence (Table S1), we introduced the desired codon changes into the HSP90rr coding sequence and 
placed the mutated and veriied genes in the shuttle expression plasmid pTLv627. he various mutated HSP90rr 
transgenes were then stably transfected under G418 selection in L. donovani strain 1SR. Faithful transcription 
from the transgenes was veriied by transgene-speciic RT qPCR (not shown).
he growth kinetics of parasites expressing the transgenes for HSP90wt, HSP90rr and mutants thereof were 
monitored in the absence of RAD and found to be indistinguishable (not shown), indicating that the expression 
of HSP90wt from the chromosomal gene copies masks the mutant phenotypes, leading us to conclude that none 
of the mutations has a dominant negative efect.
ơǦin vitroǤ To assess the efect of the P-site mutations in HSP90rr 
on in vitro growth, we seeded promastigotes in medium without selective antibiotic and added RAD at 90% 
growth-inhibitory concentration (IC90). Cell density was then monitored over 4 days. he density of HSP90rr 
cells ater 96 h was then deined as 100% growth and parasites expressing the non-RAD-resistant HSP90wt trans-
gene were taken as standard for the loss of HSP90 function.
Mutations in the N-terminal ATPase domain of HSP90rr at hr21 and hr100 both had deleterious efects on 
the proliferation under RAD inhibition (Fig. 2A). Interestingly, both hr to Ile (non-phosphorylatable) and hr 
to Asp (phosphomimetic exchange) had the same efect, suggesting that the phosphomimetic exchange was not 
functional.
All three known or suspected P-sites in the charged linker domain (CLD), hr211, hr216 and hr223, were 
mutated into alanine or aspartate, respectively. All mutations caused a signiicant ~30% reduction of the in vitro 
growth rates compared to the parental HSP90rr transgene, but no diferences between alanine and aspartate 
exchanges were observed. Combined mutations of both hr211 and hr216 had signiicant additive efects, reducing 
growth by up to 65% (Fig. 2B).
Both mutations in the middle domain (MD) of HSP90rr caused a significant growth retardation of 
55% for Ser289Ala and 25% for Ser526Ala (Fig. 2C). Since the MD is thought to specify client protein ainity, 
phosphorylation-mediated changes may afect client protein recognition.
Two pairs of adjacent P-sites were targeted in the C-terminal domain which is important for the interaction 
with co-chaperones 27 and for HSP90 dimerisation. For this analysis, the P-sites Ser594, Ser595, hr693 and Ser694 
were mutated into Ala or Asp, respectively. While the Ser594Ala exchange caused a signiicant (~50%) reduction 
of in vitro growth, the Ser594Asp exchange abolishes parasite growth entirely. he Ser595Ala exchange also caused 
a signiicant but weaker (~25%) reduction of the in vitro growth, but the Ser595Asp exchange facilitates parasite 
proliferation at ~100%. he hr693Ala but not the hr693Asp mutation reduced growth by ~20%. A strong efect 
was observed for Ser694Asp where a permanent negative charge completely abrogates promastigote growth under 
RAD challenge. By contrast, the Ser694Ala exchange had no signiicant efect (Fig. 2D).
ơǤ HSP90 plays a pivotal role in L. 
donovani life cycle control. Inhibition of HSP90 by geldanamycin or radicicol induces promastigote-to-amastigote 
conversion in the absence of elevated temperature and/or acidic pH20,26,27,61. Morphologically, this leads to 
a change of the cell shape from spindle-shaped to ovoid and to the shortening of the lagellum27. We there-
fore analysed length and width of the cell body and length of the lagellum of L. donovani transfected with the 
P-site-mutated HSP90rr variants 72 h ater RAD treatment, using either scanning electron microscopy (SEM, 
Fig. 3A)27 or anti-tubulin labelling and luorescence microscopy (Fig. 3B)38. he lengths of the mutants were 
compared to the lengths of HSP90rr and HSP90wt over expressing parasites (Fig. 3A,B).
While the parasites bearing the HSP90rr transgene maintain a spindle shape with a long lagellum (~9 µm cell 
body length, ~1 µm cell body width, ~4 µm lagella length) ater a 72 h RAD treatment, the cells over expressing 
Figure 2. Impact of phosphorylation site mutations on the in vitro proliferation. L. donovani promastigotes 
were seeded at 1 × 106 cells ml-1 in Medium199 containing radicicol at IC90 (batch-dependent; 0,5-1,25 µg/ml)  
and allowed to proliferate for 96 h. Median (±range) cell density was recorded and plotted as [%] relative to 
the cell density of promastigotes expressing HSP90rr. Standard one-letter amino acid codes apply. (n.s.): not 
signiicant, (***): p ≤ 0.001 by U-test; n = 8. (A) ATP-binding pocket mutations. (B) Charged linker domain 
mutations. (C) Middle domain mutations. (D) C-terminal domain mutations.
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the non-RAD-resistant HSP90wt are shorter, with a slightly but signiicantly shorter lagellum (~6 µm cell body 
length, ~2 µm cell body width, ~3.5 µm lagellar length) (Fig. 3A).
Changing the two N-terminal P-sites hr21 and hr100 to Ile or to Asp abrogates the ability of HSP90rr to pro-
mote the promastigote shape under RAD challenge. For all these mutants, we observed a signiicant reduction of 
the cell body length to ~5–6 µm, an ovoid cell shape with an increase of the cell body width to ~3 µm and a signif-
icant reduction of the lagellum to ~2 µm. he hr100Asp exchange in particular resulted in damaged cells under 
RAD treatment (Fig. 3C) and non-viable promastigotes. herefore, it was impossible to obtain measurements of 
this mutant.
Due to the closeness of the positions hr211 and hr216 we created double Ala-mutants (hr211/hr216Ala) and 
analysed only the morphology of the double mutant due to its indistinguishable growth phenotype from the sin-
gle mutants (Fig. 2A). he simultaneous Ala-exchange of these two hr-residues (hr211/hr216Asp) in the CLD 
reduces the cell body length signiicantly to ~6 µm and the lagellum length to ~2.5 µm under RAD. he cell body 
width is also signiicantly increased.
Peculiar morphologies correlate with the mutations at hr223. hr223Ala causes a shortening of the cell body 
(~6 µm), but normal cell body width and lagellar length (~4 µm), reminiscent of metacyclic promastigotes62. he 
cell body length phenotype is reversed in the phosphomimetic hr223Asp mutant (8–9 µm), which however shows 
a shortened lagellum. his result hints at an involvement of hr223 phosphorylation in the maintenance of the 
procyclic promastigote.
he middle domain P-sites Ser289 and Ser526 are also critical for maintaining spindle shape. he Ala-exchanges 
at these positions render the cells shorter (Ser289Ala: ~6 µm, Ser526Ala: ~7 µm) with a reduced lagellum (Ser289Ala: 
~2 µm, Ser526Ala: ~2 µm).
he impact of the mutations at the C-terminus of HSP90rr were analysed by luorescence microscopy using 
anti-tubulin antibodies. his showed identical efects when comparing HSP90wt and HSP90rr over expressing 
cells (Fig. 3B). he Ser594Ala mutation slightly reduces cell body length (~8 µm) and the length of the lagellum 
(~5.5 µm). he cell body width is slightly increased (~3 µm). he mutation Ser594Asp in contrast has a strong 
and signiicant impact on the promastigotes morphology, with a shortening of the cell body length to ~7 µm 
and the lagellum to ~4 µm. he cell body width of these mutants is signiicantly enlarged to ~4 µm. he muta-
tions Ser595Ala and Ser595Asp have no signiicant efects on the cell body lengths, but increased the cell body 
widths slightly and decreased the length of the lagella to ~6 µm. Also for hr693Ala and hr693Asp we observed 
an intermediate impact of the mutations on the cell morphology. Ser694Ala has no impact on the cell body length 
Figure 3. Morphological analysis of recombinant L. donovani populations. L. donovani promastigotes were 
seeded at 1 × 106 cells ml-1 in Medium199 containing radicicol at IC90 (batch-dependent; 0,5-1,25 µg/ml) and 
allowed to proliferate for 72 h. he cells were ixed and then visualised by SEM or luorescence microscopy using 
anti-α-tubulin mAb. By using image analysis, the cell body lengths of 50 (in µm, upper panels), the cell body 
widths of 25 (in µm, middle panels) and the lagella lengths (in µm, lower panels) of 25 randomly selected cells 
were analysed and mean values were compiled. Bars represent the mean measurements with SEM, n = 25. (n.d.): 
not detectable, (n.s.): not signiicant, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, respectively, by U-test. (A) analysis 
performed by using SEM images. (B) analysis performed by using luorescence microscopy images. (C) SEM 
images of HSP90rr and HSP90rr-T100D expressing cells -RAD and + RAD.
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(~10 µm) with a slight increase of the cell body width. he length of the lagellum is slightly but not signii-
cantly reduced. hese morphological promastigote-like features are reversed by the phosphomimetic exchange 
Ser694Asp. he mutation Ser694Asp reduces the cell body length (~7 µm) and the length of the lagellum (5 µm). 
he cell body width is signiicantly enlarged to ~5 µm.
he observed impact on the morphologies of the HSP90 variant-expressing parasites largely relects their 
growth rates under RAD. One exemption to this correlation is the hr223 site where lack of phosphorylation 
appears to drive the mutant towards metacyclogenesis.
ơin vitroǤ Several P-sites in HSP90 were identiied pre-
viously34 or in this paper as being preferentially phosphorylated in amastigotes by comparative phosphopro-
teomics of promastigote and axenic amastigote lysates (see Results, 1st section). While axenic amastigotes are 
convenient models for stage conversion, we were interested in the impact of phosphorylation on the intracel-
lular survival of true L. donovani amastigotes. Testing the sensitivity of primary mouse bone marrow-derived 
macrophages against RAD, we found that the concentrations required to render L. donovani dependent on the 
episomal HSP90rr gene variants already afected the ability of the macrophages to support a Leishmania infection 
(not shown). We therefore decided to pre-treat the parasites bearing the HSP90rr transgenes with RAD for 48 h 
prior to macrophage infection to avoid exposure of the host cells to RAD, as described previously27. he efects 
of the various HSP90rr mutants on the in vitro infectivity were analysed 48 h post-infection and compared with 
the recombinant cells bearing the resistant HSP90rr transgene and the HSP90wt over expressing cells (Fig. 4). We 
applied a duplex qPCR approach to quantify the ratio of parasite actin to macrophage actin DNA as described 
previously63.
Under these conditions, over expression of HSP90rr prevents a loss of infectivity due to the RAD treatment, 
resulting in a signiicantly higher median infection ratio compared with HSP90wt over expressing parasites, with 
diferences slightly varying between individual experiments (Fig. 4A–F).
he hr21Ile mutation resulted in ~50% reduced parasite load, albeit twice as high as the HSP90wt control, 
while the phosphomimetic exchange hr21Asp reduced the parasite load even below HSP90wt levels. he muta-
tions hr100Ile and hr100Asp both lower the parasite load by ~60% (Fig. 4A). Obviously, the putative P-sites hr21 
and hr100 that are located in the ATP-binding domain are not only critical for promastigote growth but also for 
infection of macrophages. Surprisingly, the hr100 mutants support increased intracellular persistence compared 
with the HSP90rr control, in spite of their inability to support growth of the promastigote (Fig. 2).
The Ala-exchanges at the P-sites in the charged linker region, Thr211Ala and Thr216Ala, resulted in 
non-signiicantly reduced parasite loads (Fig. 4B). he phosphomimetic exchange hr211Asp further lowered the 
parasite to host cell ratio, arguing against a simple ionic efect of phosphorylated hr211. hr216Asp by contrast 
restored infectivity signiicantly over the hr216Ala mutant (Fig. 4B). Phosphorylation of hr216 therefore appears 
to boost intracellular persistence of L. donovani.
he hr223Ala exchange also afected infectivity, reducing parasite loads in macrophages to 57% (Fig. 4C, 
Table 2). However, the phosphomimetic hr223Asp exchange cannot restore infectivity signiicantly, also arguing 
against simple ionic efects of phosphorylated hr223.
he phenotypes of Ser289Ala and Ser526Ala mutations, which are located in the middle domain, are not signif-
icant and suggest a rather limited efect on virulence (Fig. 4D).
he Ser594Ala, Ser595Ala and Ser595Asp mutations in the C-terminal region of HSP90rr reduce infectivity 
slightly but signiicantly by ~20–30% (Fig. 4E). By contrast, the cells expressing the phosphomimetic Ser594Asp 
mutant were unable to establish an infection (Fig. 4E). his is presumably caused by the inability of these trans-
genic parasites to grow under RAD in vitro (Fig. 2D).
We also tested the efects of the mutated putative P-sites hr693 and Ser694 located directly in front of the STIP-1 
recognition motif 27 at the extreme C-terminus of HSP90. he exchanges hr693Ala, hr693Asp and Ser694Ala do 
not afect infection ratios. However, the phosphomimetic Ser694Asp exchange abrogates intracellular survival 
completely (Fig. 4F). Like Ser594Asp, the Ser694Asp mutant of HSP90rr is unable to promote promastigote prolif-
eration under RAD (Fig. 2D), suggesting an inability to tolerate the pre-treatment before infection.
Ƥ ? ?in vitro ?Ǥ ?Ǥ To gain insight into the mechanisms 
involved in HSP90 regulation, we investigated whether kinases that have been described to target mammalian 
HSP90 may also target Leishmania HSP90. In particular, we focused on three protein kinases, GSK-3, CK1.2 and 
DYRK1. Of these, GSK-3 and CK1.2 have been shown to phosphorylate the C-terminal domain of mammalian 
HSP90. his phosphorylation is particularly important to prevent the binding of HSP90 to CHIP, a co-chaperone 
containing an ubiquitin ligase activity and thus to prevent the client protein from being degraded32. We also 
selected DYRK1 as it has been shown to be a priming kinase for GSK-3; it phosphorylates the substrates on 
a speciic site which can be recognised and phosphorylated by GSK-364. herefore, we expressed and puriied 
recombinant L. major CK1.2 51, L. major GSK-365 and L. infantum DYRK1 to perform in vitro kinase assays using 
recombinant L. donovani HSP90wt.
As shown in Fig. 5B lane 4, we detected a signal at 80 kDa revealing the transfer of 32P onto HSP90 by CK1.2 
but not by GSK-3 or DYRK1 (lanes 5 and 6). In contrast, all three kinases were able to phosphorylate myelin basic 
protein (MBP), a canonical kinase substrate (lanes 1–3). Since we can exclude MBP autophosphorylation51, these 
data suggest that HSP90 is a substrate of CK1.2, which is consistent with previous indings on mammalian HSP90, 
but not a substrate of GSK-3 or DYRK1. his is diferent from mammalian HSP90 where it has been shown that 
mammalian GSK-3 phosphorylates HSP90 at its C-terminus32. his may be due to the use of the L. major (GSK3 
and CK1.2) and L. infantum (DYRK1) orthologues in our in vitro assay; however, the sequence identity between 
the GSK3 of L. major and L. donovani is 98%, and the sequence identity between the DYRK1 of L. infantum and 
L. donovani is 99%, making a complete change of client speciicity very unlikely.
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ƤǦȋȌ ?Ǥ ?Ǥ Among the P-sites that we identiied, the residues 
hr211, hr216, hr223, hr693 and Ser694, match the canonical consensus site for CK1 family members: S/T(X)2–3S/T 
or D/E(X)2–3S/T
66. To identify which of the previously studied P-sites may be targeted by CK1.2, we expressed 
HSP90 with serine or threonine to alanine mutations to test which mutation abrogates HSP90 phosphorylation by 
CK1.2. We tested mutants for all known or suspected P-sites since members of the CK1 family can phosphorylate 
canonical as well as non-canonical sites such as SLS-Xn-(E/D)n67 or K/R-X-K/R-(X)2-S/T
68,69. We performed 
in vitro kinase assays using recombinant CK1.2 with HSP90wt or HSP90 phosphosite mutants as substrates. 
As shown in Fig. 5D, HSP90-hr693Ala, -Ser694Ala and -hr693Ala/Ser694Ala mutants are still phosphorylated 
by CK1.2 at levels comparable with the wild type control, although we observe that the levels of Ser693Ala and 
Figure 4. Efects of HSP90 phosphorylation site mutations on the in vitro infectivity (A–F). Recombinant 
parasites were irst pre-treated with RAD for 48 h at IC90 and then used to infect bone marrow-derived 
macrophages (MOI 10:1). Ater 4 h, free parasites were removed and the infected macrophage cultures 
were further incubated at 37 °C and 5% CO2 for 44 h. Genomic DNAs were isolated from free and attached 
macrophages and subjected to a duplex qPCR against mouse and Leishmania actin DNA (Bifeld et al., 2016). 
he median parasite:host DNA ratio was then compiled. Abbreviations: (n.s.): not signiicant, *p ≤ 0.05, 
**p ≤ 0.01 in a one-tailed, paired Student’s t test (A), or in a two-tailed U-test (B–F); n = 6.
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Ser693Ala/hr694Ala are slightly lower than those of hr694Ala. By contrast, phosphorylation by CK1.2 was abro-
gated in hr21Ala, hr100Ala, hr211/216Ala, hr223Ala, hr289Ala, Ser526Ala and Ser594Ala and Ser595Ala mutants of 
HSP90 (Fig. 5D,F).
We also performed a “cold”, i.e. non-radioactive in vitro kinase assay with recombinant HSP90wt and CK1.2 
in the presence or absence of 10 µM D4476, a speciic CK1 inhibitor51. he samples of three independent kinase 
assays were analysed by mass spectrometry to identify the sites phosphorylated by CK1.2. We found only one 
site, Ser289 (Fig. 5G), which is phosphorylated in the presence of CK1.2 but not in the presence of CK1.2 + D4476, 
suggesting that CK1.2 targets Ser289. No phosphorylation was detected at hr211, hr216, Ser526, Ser594, Ser595 and 
hr223 in our dataset (data not shown), suggesting that they are not targeted by CK1.2. We cannot exclude that 
the sites hr21, hr100, hr693 and Ser694 may be true CK1.2 sites as the peptides containing those sites were not 
detected in our mass spectrometric analyses. However, those sites are only presumed phosphorylation sites based 
on analogies with model HSP90s. Moreover, only hr693 and Ser694 resemble canonical CK1 sites.
In summary (Table 2), mutations at the established and putative phosphorylation sites in the L. donovani 
HSP90 result in a variety of phenotypic manifestations. he most drastic and general efects are observed ater 
introducing mutations at sites within the highly conserved ATP-binding domain. hese HSP90rr variants appar-
ently cannot support growth or infectivity under RAD challenge. Mutation at sites in the charged linker domain 
show moderate efects on growth and infectivity. Middle domain site mutations result in moderate to strong 
growth inhibition, morphologic changes and a moderate loss of infectivity, even though one of them is established 
as the only CK1.2 phosphorylation site. In the C-terminal domain we observe the strongest efects for two of the 
phosphomimetic Ser-Asp exchanges with no or moderate impact of Ser/hr to Ala mutations. Clearly, permanent 
negative charges at these sites are not conducive to parasite itness. At other sites, Ser/hr to Asp restore growth, 
morphology and/or infectivity to a various extent compared with the Ser/hr to Ala mutations.

Trypanosomatida and perhaps the entire phylum Euglenozoa lack inducible transcription as a means for gene 
expression control70,71. he existing genome databases contain no conirmed genes for transcriptional regulators 
and cis-regulatory DNA sequence elements such as gene promoters and enhancer elements known from crown 
group Eukaryota. Moreover, the established mode of multicistronic transcription precludes individual transcrip-
tional control of gene expression71,72. Cis-splicing is very rare but trans-splicing has been discussed as point of 
regulation73. his leaves mRNA processing and stability, translation, protein folding and post-translational pro-
tein modiications as conceivable targets of gene expression control.
domains AA to growth [%] length [%] width [%] lagellum [%] infectivity[%] CK1.2 Substrate
HSP90rr 100.0 100 100 100 100 n.d.
HSP90 7.4 71 189 78 25 +
N domain
hr21 I 7.3 70 229 75 29 ±
D 5.1 59 247 61 11 n.d.
hr100 I 6.3 69 221 53 38 ±
D 3.9 n.d. n.d nd 10 n.d.
CL domain
hr211 A 72.9 n.d. n.d nd 79 n.d.
D 69.2 n.d. n.d nd 54 n.d.
hr216 A 69.6 n.d. n.d nd 61 n.d.
D 69.4 n.d. n.d nd 114 n.d.
hr211,216 A 52.9 76 120 64 −
hr211,216 D 37.4 n.d. n.d. n.d. n.d. n.d.
hr223 A 76.0 74 111 85 57 −
D 62.0 94 134 51 61 n.d.
M domain
Ser289 A 47.5 75 123 54 66 +
Ser526 A 71.6 80 100 54 76 −
C domain
Ser594 A 58.1 91 111 80 65 n.d.
D 6.3 76 156 57 3 n.d.
Ser595 A 74.0 98 117 87 70 n.d.
D 98.6 95 125 79 80 n.d.
Ser594/5 A n.d. n.d. n.d. n.d. −
D n.d. n.d. n.d. n.d. n.d.
hr693 A 77.9 94 125 80 91 ±
D 93.1 94 132 92 81 n.d.
Ser694 A 88.2 97 112 85 93 ±
D 6.5 65 217 60 4 n.d.
Table 2. Compilation of results. Relative (in % of HSP90rr values) in vitro growth, morphology, infectivity and 
substrate potential for CK1.2 of the tested mutants.
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Figure 5. Protein kinase of HSP90. (A) hree protein kinases, rLmCK1.2, rDYRK 1, and rGSK 1, were 
incubated with γ-32P-ATP with MBP or with HSP90wt as substrate as indicated below and analysed by SDS-
PAGE and Coomassie Brilliant Blue staining. he positions of protein size markers are indicated to the let, the 
positions of the kinases and of HSP90 are indicated on the right. (B) As in (A), but autoradiograph. (C,D) In 
vitro protein kinase assay of rLmCK1.2 with HSP90 and 5 phosphosite mutants thereof, using γ-32P-ATP. (C) 
shows a Coomassie Brilliant Blue stain, (D) shows the corresponding autoradiograph. (E,F) As in (C,D), but 
with 4 other phosphosite mutants of HSP90. (G) Mass spectrometry-based quantiication of the phosphoserine/
serine ratio at Ser289 without (−D4476) or with (+D4476) a CK1.2-speciic inhibitor. he y-axis is in log10 scale. 
All greyscale images were cropped from contiguous parts of the original image. Digital enhancements, using 
Adobe Photoshop CS3, were performed over the entire greyscale images and restricted to tonality optimisation 
and size adjustments.
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he major chaperone protein HSP90 is subject to various post-translational modiications such as phosphoryl-
ation, acetylation, s-nitrosylation, oxidation, SUMOylation or ubiquitination31,74. Post-translational modiications 
of HSP90 are known to be involved in the ine-tuning of the chaperone cycle which includes conformational 
changes, ATPase activity, interaction with co-chaperones and the recruitment and activation of various client 
proteins31,32,42,75. Diferences in this ine-tuning processes also adapt HSP90 regulation and function to the unique 
intracellular environments of diferent organisms or to various physiological states within diferent tissues of 
metazoans29,76.
Previous work showed that HSP90, HSP70 and the co-chaperone STIP1 are subject to increased phospho-
rylation during the promastigote-to-amastigote diferentiation of L. donovani34. hese data suggested that the 
function of HSP90 is adaptable to the diferent environments of the distinct life cycle stages. It was previously 
described that a heat shock of yeast cells decreases the phosphorylation level of HSP90, while an opposite efect 
was observed looking at the turnover of phosphate groups in heat-shocked HeLa cells77,78. Phosphorylation of this 
essential chaperone is one possible mechanism to adapt its function to various environmental conditions and in 
a species-speciic manner.
his paper focuses on the impact of HSP90 phosphorylation by introducing amino acid exchange mutations 
into the radicicol-resistant HSP90rr variant27 and monitoring their impact on in vitro promastigote proliferation, 
morphology, in vitro infectivity and casein kinase 1.2 substrate properties.
Phosphorylation sites are distributed over the whole polypeptide sequence of HSP90 and all putative domains. 
In our study, we included sites shown as phosphorylation sites for L. mexicana HSP90 (hr211, hr216, Ser289, Ser594, 
Ser595), L. donovani HSP90 (hr223, Ser526) and putative sites identiied by analogy (hr21, hr100, hr693, Ser694).
We observed that amino acid exchanges at the two putative phosphorylation sites hr21 and hr100 which are 
implicated in the activity of the ATPase domain from previous work in Saccharomyces cerevisae44,60,79, severely 
inhibit growth of the promastigote stage. Even phosphomimetic exchanges to Asp in both positions cannot 
restore the proliferation capacity. We can ofer three explanations for this observation, (i) the exchanges may 
render HSP90 non-functional as chaperone, (ii) the structural changes caused by the amino acid exchanges in the 
nucleotide binding pocket may impair ATP turnover, or (iii) the changes may render HSP90rr sensitive to RAD 
again. he latter view is supported by the inding that expression of these four mutant HSP90rr variants results 
in phenotypes indistinguishable from the cells that are over expressing the RAD sensitive HSP90wt (Table 2). 
While phosphorylation by casein kinase 2 at the residue hr22, equivalent to hr21 in Leishmania HSP90, was 
established for the yeast HSP9043, it was also shown that hr22Ala and hr22Glu amino acid exchanges impact on 
ATPase activity and interaction of HSP90 with co-chaperones such as AHA1 and increase the sensitivity against 
RAD and GA44. However, we could recently demonstrate that lack of AHA1 in Leishmania has no impact on 
RAD sensitivity38, arguing against an impaired HSP90-AHA1 interaction as the cause for the observed, severe 
phenotypes. Testing the mutants in vitro for ATPase activity, RAD sensitivity and AHA1 binding may shed light 
on this phenomenon in the future.
Ala and Asp exchanges at hr211 and hr216 in the highly diverged charged linker domain have opposing 
efects on the parasites’ infectivity. A stable negative charge at position 211 reduces parasite loads by almost 
50%, while the efect of a non-phosphorylatable Ala at 216 is reverted by the phosphomimetic Asp exchange. 
Although neither site could be identiied as CK1.2 phosphorylation site, a double hr-Ala exchange at 211 and 
216 abrogates CK1.2 phosphorylation of HSP90 and causes a reduction of the lagellum. Another site, hr223, also 
in the CL domain and speciic for Trypanosomatida HSP90s, moderately afects growth and infectivity, as well as 
CK1.2-dependent phosphorylation, but is no CK1.2 site itself. Of note are the efects on the morphology where 
abrogation of phophorylation (hr to Ala) reduces cell body length, but not lagellar length, thereby resembling 
the shit from procyclic to metacyclic promastigotes80. his is a irst hint at a possible role of HSP90 in the transi-
tion from proliferative procyclic promastigotes to the infective metacyclic form. he hr223Asp exchange restores 
cell body length, but increases diameter and reduces lagellar length, resembling early amastigote development. 
his its with the identiication of hr223 as an amastigote-speciic phosphorylation site
34.
In the middle domain, which in model HSPs has a function in client protein recognition60,81, we analysed two 
sites, Ser289 and Ser526. Ser289 has an impact on proliferation and the maintenance of promastigote morphology. 
It was also identiied as the only CK1.2 site known so far in HSP90, and its replacement with Ala reduces in vitro 
infectivity by 24%. Ser526, an amastigote-speciic site
34 moderately afects growth, virulence, lagellar length and 
CK1.2 phosphorylation, either at Ser289 or at Ser526, since this site was not detected in mass spectrometry. It is 
conceivable that the efects of hr211/216, hr223 and Ser526 are at least in part due to their impact on Ser289 phos-
phorylation by CK1.2. he question remains open how mutations at hr21, hr100, hr211,216, hr223,but also Ser526, 
Ser594, and Ser595 can afect phosphorylation at Ser289.
The C-terminal domain of HSP90 chaperones is known to facilitate dimerisation and interaction with 
co-chaperones STIP127 and prolyl-peptidyl isomerases such as cyclophilin 4040,82 and others. Four phospho-
rylation sites were detected or inferred by analogy. Replacement of Ser594 caused a ~40% reduction of in vitro 
growth and infectivity while the Ser694 to Ala change had little impact. However, the phosphomimetic Ser-to-Asp 
exchange in these positions completely abrogated HSP90-dependent growth and infectivity. We conclude that 
permanent negative charges in these positions have a deleterious efect on the HSP90 functionality. he HSP90 
reaction cycle is known to include the ordered assembly and disassembly of HSP90-co-chaperone complexes at 
the C-terminal domain83, possibly requiring frequent reversal of post-translational modiications, such as phos-
phorylation. A permanent negative charge may therefore impede the ordered transitions of the HSP90 foldosome 
complex. he efects observed for mutation in two other sites, Ser595 and hr693, are moderate by comparison.
One lesson from our data is the strong deleterious efects of presumed phosphomimetic Asp mutations. Unlike 
MAP kinases where Asp replacements in the activation sites render downstream kinases permanently active, the 
situation in HSP90 with its multiplicity of active phosphorylation sites and a complex reaction cycle with multiple 
partnering chaperones and co-chaperones may be too complicated for simplistic approaches. Another problem 
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resides in our experimental set-up where we express RAD-resistant, mutated HSP90rr before a strong back-
ground of RAD-sensitive, endogenous HSP90. A treatment with RAD is necessary to express the mutant pheno-
types, yet one cannot exclude interactions and even heterologous complexes of HSP90rr and HSP90 monomers. 
For example, the HSP90-STIP1 interaction is not afected by RAD treatment27, opening up the possibility that 
phenotypes of mutations outside the ATP binding pocket are “watered down” by interaction with endogenously 
coded HSP90wt. To rectify this problem, we hope for a future implementation of advanced reverse genetics such 
as CRISPR/cas9 based gene editing84,85 to eliminate the entire cluster of ~17 tandemly arranged HSP90 gene cop-
ies and to express the mutant HSP90s before a null mutant background.
So far, not much is known about the upstream and downstream players in the presumed signal transduction 
pathways. In the eukaryotic model organisms, from yeasts to humans, signal transduction pathways govern the 
activity of many gene expression regulators through reversible phosphorylation86. Many of these regulators are 
trans-acting transcription factors, a protein class that is almost entirely absent from the Leishmania proteome71. 
herefore, post-transcriptional regulation, in particular on the protein synthesis and protein modiication lev-
els, are important for Trypanosomatida49,87. How these processes are linked to the signal transduction pathways 
remains one of the most important questions in the ield. Since HSP90 and its co-chaperones are integral parts of 
the signal transduction pathways governing the Leishmania life cycle20,27,61 and are targets of stage-speciic phos-
phorylation events34, the post-translational modiication of HSP90 is likely to have multiple efects on Leishmania 
viability and itness, some of which were uncovered in our analysis.

LǤdonovaniǡin vitroǤ L. donovani 1SR88 
were cultivated as described27. Batch-speciic IC90 were determined for radicicol (Sigma-Aldrich, München, 
Germany) prior to each experiment. Concentration range was 0.5–1.25 µg/ml. Electrotransfection and antibiotic 
selection of L. donovani promastigotes was carried out as described27.
In vitroǤ In vitro infection of murine bone marrow-derived macrophages with RAD-treated 
L. donovani promastigotes was performed as described earlier27 with two modiications: (i) bone marrow mac-
rophage precursor cells were diferentiated using 10–30% supernatant of LADMAC cells89, and (ii) quantii-
cation of infections were performed by quantitative PCR63. Adherent BMMs were infected at a multiplicity of 
infection of 10 parasites per macrophage. Ater 4 hours of incubation at 37 °C in DMEM/F-12, supplemented 
with GlutaMAX, free parasites were removed by 3 washing steps with PBS, and the infected cells were incu-
bated at 37 °C and 9% CO2 for another 44 hours. At 48 h post-infection, free cells in the culture supernatant and 
attached cells were pooled by sedimentation and lysed. Genomic DNA (gDNA) was isolated from the infected 
cells using the ISOLATE II Genomic DNA Kit (Bioline, Luckenwalde, Germany). Parasites were then quantiied 
by semi-quantitative real-time PCR (qPCR) targeting host cell and parasite actin-coding genes with double labe-
led probes and using total parasite and host gDNA as the template63. he relative parasite load was deined as the 
ratio of parasite actin DNA against mouse actin DNA.
 ? ?ǦǤ he generation of the RAD-resistant HSP90 
variant (HSP90rr) was described earlier27. Plasmid pUC:HSP90rr served as template for site-directed mutagen-
esis. Primers (Supplementary data, Table S1) were phosphorylated using ATP and polynucleotide kinase (PNK, 
New England Biolabs)90 and then used to prime a PCR ampliication of pUC:HSP90rr using the iProof-PCR kit 
for GC-rich DNA (#172–5320) from Bio-Rad Laboratories (München, Germany). Following ampliication (30 
cycles), the linear PCR product was subjected to ligation (3 h, RT) to form circular plasmids. hese were then 
used to transform competent E. coli DH5-α cells (#18265–017, Invitrogen, Karlsruhe, Germany). Ater ampliica-
tion and puriication90 via caesium-chloride density gradient ultracentrifugation (50% w/v CsCl, 6 h, 90,000 rpm, 
20 °C, rotor NVT90, Beckman, Krefeld, Germany), the pUC:HSP90rr-derived mutants were veriied by DNA 
sequencing (LGC Genomics, Berlin, Germany).
he derivative of the plasmid pJC4591, pJC45:HSP90, was also used for site-directed mutagenesis. he same 
set of primers (Table S1) was used. PCR, ligation, transformation of E. coli and CsCl puriication of plasmids were 
performed the same as for the site-directed mutagenesis of pUC:HSP90rr.
Ǥ The expression plasmid pTLv6 has been 
described27. Mutated HSP90 coding sequences derived from pUC:HSP90rr were excised with enzymes KpnI 
and BamHI (compatible with BglII sticky ends) and ligated into linearised pTLv6 to create the pTLv6:HSP90rr 
expression plasmids coding for the various HSP90rr variants with P-site codon exchanges.
ƤǤ Semi-quantitative real-time RT-PCR was performed essentially as described92. HSP90 
transgene-speciic primers were pTLv6.HSP90.F2 (CGACGAGGAGGAGGAGGCAG) and pTLv6.HSP90.B1 
(GCCAGTACATCACAAGACTC ATAGATCC). HSP90 mRNA abundance was calculated relative to the actin 
signal.
ȋȌǤ Leishmania cells were cultivated for 72 h without RAD or with 
the IC90 of RAD. he treated and non-treated cells were then washed twice in PBS, ixed in 2% glutaraldehyde in 
sodium cacodylate bufer and postixed with 1% osmium. Samples were dehydrated at increasing ethanol concen-
trations (30–100%). Ater critical point drying, samples were treated with gold and analysed on a Philips SEM 500 
electron microscope. Images were taken using a conventional 35 mm camera, and the developed black-and-white 
ilms were digitalised using a HAMA 35 mm ilm scanner.
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	Ǥ Promastigote cells were incubated for 72 h without RAD or with the IC90 of 
RAD. Ater the incubation period, cells (1 × 107 cells) were sedimented, washed twice with PBS and suspended in 
1 ml of PBS. Aliquots of the suspension (2 × 105 cells) were applied on microscopic slides and air-dried. Ater ix-
ing the cells for 2 min in ice-cold methanol, the slides were air-dried for 20 min. Non-adherent cells were removed 
by gentle washing (0.1% Triton X-100 in PBS) followed by incubation in blocking solution (2% BSA, 0.1% 
Triton-X 100 in PBS). Slides were then incubated for 1 h with monoclonal mouse anti-tubulin (Sigma-Aldrich, 
München, Germany, 1:4000), washed thrice and then incubated for 1 h with anti-mouse Alexa 594 (Dianova, 
Hamburg, Germany, 1:250) and DAPI (Sigma-Aldrich, München, Germany, 1:25). Ater washing the slides thrice, 
Mowiol and coverslips were applied and the slides were let to dry for 24 h at 4 °C. Fluorescence microscopy was 
carried out on an EVOS FL Auto epiluorescence microscope (Life Technologies, Darmstadt, Germany).
Ǥ Leishmania mexicana MNYC/BZ/62/M379 promastigotes were cultured in SDM-
79 medium93 supplemented with 10% heat-inactivated FCS (Sigma, Steinheim, Germany), 7.5 µg ml−1 hemin 
(Sigma, Steinheim, Germany) and 100 U ml-1 penicillin/100 µg ml-1 streptomycin (Pen/Strep; Gibco, UK). 
Cultures were incubated at 27 °C until they reached a density of 4–5 × 107 parasites ml-1 (late-log phase). Cultures 
were either harvested or diferentiated into amastigotes by inoculation in Schneider’s Drosophila medium (PAN 
Biotech, Aidenbach, Germany) supplemented with 20% FCS (PAN Biotech), 2 mM L-glutamine, 100 U ml-1 Pen/
Strep, and 20 mM 2-morpholinoethane sulfonic acid monohydrate [MES, pH 5.5] (Serva, Heidelberg, Germany). 
Cultures were incubated at 34 °C/5% CO2 for 72 h. Parasites were harvested by centrifugation at 2000 × g, 4 °C, 
and washed in 1) ice-cold wash bufer (21 mM HEPES pH 7.5, 137 mM NaCl, 5 mM KCl) and 2) ice-cold wash 
bufer with protease and phosphatase inhibitors (1 mM Na-orthovanadate, 0.1 µM okadaic acid, 10 mM NaF, 
10 mM o-phenanthroline, EDTA-free protease inhibitors). For lysis, parasites were resuspended in a solution of 
7 M urea, 2 M thiourea, 40 mM Tris, 1% n-octyl-β-D-glycopyranoside, 1 mM MgCl2, 1 mM o-phenanthroline, 
300 U benzonase, 1 mM Na-pervanadate (Na-orthovanadate activated in 18% H2O2), protease inhibitors (Roche 
EDTA-free protease inhibitor tablets), and phosphatase inhibitor cocktails (P2850 and P5726 from Sigma), and 
sonicated for 3 × 15 s on ice. Lysates were incubated at −80 °C for 30 min prior to reduction (50 mM DTT) and 
alkylation with 50 mM iodoacetamide. Proteins were precipitated in an 8-fold excess of ice-cold acetone-ethanol, 
1:1, v/v, by overnight incubation at −20 °C.
Protein precipitates were reconstituted in 6 M urea/2 M thiourea and diluted in 50 mM NH4HCO3 for digestion 
with trypsin at a 1:75 enzyme-substrate ratio overnight. Digestion was quenched by addition of formic acid (FA) 
to a inal concentration of 1%. Aliquots of 330 µg digested proteins were used for phosphopeptide enrichment 
by TiO2 (Titansphere, 5 µm; GL Sciences, Tokyo, Japan). Enrichment was performed with home-made columns 
packed in p200 pipette tips, essentially as described before94. Samples for LC-MS/MS were prepared by desalt-
ing on Stop And Go Extraction (STAGE)-tips95. A plug of C8 (phosphopeptides) or C18 (non-phosphorylated 
peptides) Empore disc (3 M Bioanalytical Technologies, St. Paul, MN, USA) was placed in the thin end of an 
ordinary p200 pipette tip and washed in 100% acetonitrile (MeCN). he reversed-phase (RP) material was equil-
ibrated with 5% FA and the sample loaded in a 1:1 sample-to-5% FA volume ratio. Peptides were eluted into a 
clean microcentrifuge tube by 70% MeCN/5% FA and vacuum-dried. Upon preparation for LC-MS/MS analy-
sis, peptides were reconstituted in 0.4 µl 100% FA and diluted with a suitable volume of 0.1% FA. Samples were 
analysed on LTQ Orbitrap XL mass spectrometers (hermo Fisher Scientiic, Bremen, Germany). For peptide 
separation, an Easy-nLC™-system (hermo Fisher Scientiic (previously Proxeon), Odense, Denmark) was cou-
pled directly to the mass spectrometer. he Easy-nLC™ was itted with a home-made analytical column (50 µm 
i.d.; 100 µm o.d., 18 cm) (ReproSil-Pur C18-AQ, 3 µm; Dr. Maisch, GmbH, Ammerbuch-Entringen, Germany). 
Phosphopeptides were analysed using collision induced dissociation (CID) MultiStage Activation (MSA) in an 
MS/MS Top10 set-up for fragmentation of the 10 most intense peptide peaks in each MS scan with 45 seconds 
exclusion time.
Ǥ he LCMS data were processed 
with DTASuperCharge96 and searched against the TriTrypDB L. mexicana database (version 4.0) (TriTrypDB, 
http://tritrypdb.org/tritrypdb) using an in-house Mascot server (version 2.2.06, Matrix Science, London, UK). 
Mascot searches were conducted with 5 ppm peptide tolerance and 0.6 Da fragment ion tolerance. For database 
searches, cysteine carbamidomethylation was included as a ixed modiication, while oxidation of methionine, 
Gln → pyro-Glu (N-term Q), Glu → pyro-Glu (N-term E), pyrocarbamidomethyl (N-term C) and phospho (S, 
T, and Y) were added as variable modiications. Data sets were compiled in Scafold (version 3.3.1, Proteome 
Sotware Inc., Portland, OR, USA) with a protein threshold of minimum 95% and a peptide threshold of min-
imum 95% for at least 1 peptide. he phosphorylated proteins fulilling these criteria were further evaluated in 
Scafold PTM (version ScafoldPTM_1.1.3, Proteome Sotware Inc., Portland, OR, USA).
Phosphorylation sites were validated by a semi-automatic approach, applying Ascore97 in combination with 
Mascot Delta Score98 and manual inspection of selected spectra. Phosphorylation sites with Ascores >19 were 
accepted unconditionally.
Ƥ ?Ǥ ? ? ?Ǥ For identiication of CK1.2 
phosphosites, we performed three independent cold kinase assays that were then transferred into fresh tubes 
to perform in-solution digestion, according to standard protocols. Briely, ater reduction (to a inal concen-
tration of 5 mM DTT) and alkylation (to a inal concentration of 10 mM iodoacetamide) samples were diluted 
10-fold with ammonium bicarbonate and incubated overnight with 0.2 µg trypsin/LysC (Promega) at 37 °C. 
Samples were then loaded onto a homemade C18 stage tip for desalting. Desalted samples were reconstituted in 
2% MeCN/0.3% TFA and analysed by nano-LC-MS/MS by using an RSLCnano system (Ultimate 3000, hermo 
Scientiic) coupled to an Orbitrap Fusion Tribrid mass spectrometer (hermo Fisher Scientiic). Peptides were 
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analysed using HCD fragmentation with normalised collision energy of 30, in a top speed mode with 45 seconds 
exclusion time. Spectra were interrogated by SequestTM through Proteome DiscovererTM 2.1 (hermo Scientiic) 
with the in-house database containing the sequences of the Leishmania HSP90, the Leishmania casein kinase 
1 (E9AHM9, E9AHM8 and A4IAZ8) and the most abundant contaminants (244 protein sequences). Enzyme 
speciicity was set to trypsin and a maximum of two missed cleavage site were allowed. Oxidised methionine, 
N-terminal acetylation, phosphorylation of Ser, hr and Tyr and carbamidomethyl cysteine were set as variable 
modiications. Maximum allowed mass deviation was set to 10 ppm for monoisotopic precursor ions and 0.6 Da 
for MS/MS peaks. he resulting iles were further processed using myProMS99. FDR calculation used Percolator 
and was set to 1% at the peptide level for the whole study. We validated phosphorylated peptides by combining 
the phosphoRS information and by manually inspecting the peak assignment.
To quantify the phosphorylated S289 peptide, we extracted from the MS survey of the nanoLC-MS/MS raw 
iles the extracted ion chromatogram (XIC) signal by using the retention time and m/z values of the well charac-
terised tryptic peptide ions using the Xcalibur sotwares (manually). XIC areas were integrated in Xcalibur under 
the QualBrowser interface using the ICIS algorithm. Areas were normalised by using the non-phosphorylated 
ion’s signal100. Mean values and standard deviation were calculated from three independent experiments.
 ? ?Ǥ he constructs for the expression of 
recombinant wild type or mutated HSP90 were introduced into E. coli BL21(DE3) [pAPlacIQ] and expression was 
induced using 0.4 mM IPTG at 37 °C for 2 h101. he His-tagged proteins were puriied using a Ni-NTA column 
(Qiagen), as per the manufacturer’s instructions. Purity of the proteins was veriied by SDS-PAGE and Coomassie 
Brilliant Blue staining. he puriied proteins were used for the kinase assays.
Ƥ ?Ǥ ?Ǧ ?Ǧ ?ǡ
 ?Ǥ he L. major 
Friedlin GSK-3 short open reading frame (LmjF18.0270, LmaGSK-3s) was amplified from genomic DNA, 
cloned into the pTriEx-1.1 vector (Novagen) as previously described48,102, while a synthetic ORF of the L. infan-
tum DYRK1 (LinJ.15.0180), optimised for codon usage in E. coli, was synthesised in pET14b (EMBL, BamHI/
XhoI sites) to encode a His6-LinDYRK1 protein (git from Dr Vinicius Pinto Rocha and Dr Milena Soares). 
LmCK1.2-V5-His6 (LmjF.35.1010)51, GSK-3 and DYRK1 were introduced into E. coli BL21 Rosetta. he expres-
sion of recombinant kinases was induced for 4 hr, with 1 mM IPTG at 37 °C or RT for GSK-3 and DYRK1 respec-
tively, while CK1.2 was expressed with 0.02% (w/v) arabinose at RT as previously described51. The His-tag 
proteins were puriied using Co-NTA agarose (Pierce) as previously described51.
In vitroǤ In vitro kinase assays were performed as described51. Briely, recombinant CK1.2 
(rCK1.2), GSK-3 and DYRK1 were assayed in bufer C (60 mM β-glycerophosphate, 30 mM p-nitrophenyl phos-
phate, 25 mM MOPS, 5 mM EGTA, 15 mM MgCl2, 1 mM dithiothreitol, 0.1 mM sodium vanadate, pH 7.0) with 
15 µM γ-32P-ATP in 30 µl inal volume. For the identiication of the CK1.2 phosphosites in HSP90, a similar 
experiment was performed using CK1.2, recombinant HSP90 and cold ATP at 15 µM. We used the following 
substrates: 2 µg of either recombinant HSP90, recombinant HSP90 mutants or 4 µg of myelin basic protein (MBP, 
Sigma-Aldrich), except if stated otherwise. he MBP used was batch-tested previously for absence of autophos-
phorylation51. Ater a 30 min incubation at 30 °C in a 20 µl reaction volume, the reaction was stopped by adding 1 
volume 2 × loading bufer103. he incorporation of γ-32P-ATP was monitored by SDS-PAGE and autoradiography. 
Samples for mass spectrometry analysis were prepared identically, but with non-labelled ATP.
In silicoǤ DNA and protein sequence analysis was performed using the MacVector® sotware 
(versions 12 to 16). Numerical data were analysed using the Prism® sotware (version 5). Greyscale and colour 
images were optimised for contrast using Photoshop® CS3 (Adobe). Composite igures were assembled using the 
Intaglio® sotware (Purgatory). For the length measurements of cells, the digital images were imported into the 
ImageJ 1.42q sotware (Wayne Rasband, National Institute for Health, USA) analysed using the measurement line 
tool. Measurements in centimetres were then normalised using the integrated size bars. For the analysis of the 
cell body lengths 50 randomly selected cells were measured. For the analysis of the cell body widths and lagella 
length 25 cells were analysed. Signiicance was determined using the two-sided U-test104. All greyscale images 
were cropped from contiguous parts of the original image; no recombination of lanes was performed. Digital 
enhancements, using Adobe Photoshop CS3, were performed over the entire greyscale images and restricted to 
tonality (curve) optimisation and size adjustments.

All data and materials generated for this study may be obtained from the corresponding author upon written 
request with the stipulation that any work derived from the data and materials will cite the source.
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